Abbott Laboratories (ABT) shares snapped six straight sessions of losses, as the stock closed 1.2% higher at $108.77 on Monday.
The MedTech giant started its downward trend on Jan. 15. The stock has lost over 13% in the preceding six sessions.
ABT closed 1% lower on Friday at $107.42. January has been a less favorable month for the company, as it traded 12 sessions in red and just three sessions in green.
Last week, the Illinois-based company’s shares closed 10% lower on Thursday after it reported lower-than-expected revenue for Q4 2025 following underperformance in its Nutrition segment.
Looking at Seeking Alpha’s Quant Rating, ABT has a Hold rating with a score of 3.06 out of 5. The company received A+ in the prospect of profitability, while it got D- in the growth factor.
Turning to the Wall Street community, 21 analysts gave ABT a Buy and above, eight analysts have given the stock a Hold recommendation, and no one recommended Sell or lower. Seeking Alpha analysts are also bullish and see the stock as a Buy.
“The recent pullback in Abbott Laboratories appears to be driven more by short-term sentiment than by any deterioration in its long-term fundamentals. Near-term weakness in the Nutrition and Diagnostics segments has pressured results. However, ABT continues to deliver solid earnings growth, expanding margins, and strong performance in high-growth areas,” pointed out a recent Seeking Alpha analysis by Gen Alpha.
Another Seeking Alpha analysts also argued that a post-earnings sell-off and a price dip are buying opportunities for investors.
Earlier in the day, Abbott said its Chairman and CEO Robert Ford purchased 18.8K of the company’s stock recently with a value of just over $2M.
The stock rose 10% last year, compared to the 16% rise in the broader S&P 500 Index.